Overview

Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers

Status:
NOT_YET_RECRUITING

Trial end date:
2026-03-01

Target enrollment:

Participant gender:

Summary

The trial is to compare the bioavailability of the original European Lasix (furosemide injection) administered in accordance with its prescribing information with the same dose of a novel furosemide formulation developed for this subcutaneous administration. The study will also investigate PK and PD of these regimens.

Phase:

PHASE1

Details

Lead Sponsor:

SQ Innovation, Inc.

Collaborator:

BDD Pharma Ltd